Matinas BioPharma receives listing deficiency notice, granted plan period through October 2027
Matinas BioPharma Holdings received notice on June 24, 2026 from NYSE American that it failed to meet continued listing standards under Section 1003(a)(ii) of…
$4.0Mequity$3.0Mequity